Abstract
Background Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.
Methods A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.
Results MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade IV without IDH mutations had a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade II received multiple sclerosis diagnosis mostly at the same time or later. Concurrent MS was associated with a lesser extent of tumor resection and a worse prognosis in IDH-mutant glioma patients (PFS 32 vs. 64 months, p=0.0206). When assessing tumor-intrinsic differences no distinct subgroup-defining methylation pattern was identified in gliomas of MS patients compared to other glioma samples. However, differential methylation of immune-related genetic loci including human leukocyte antigen locus on 6p21 and interleukin locus on 5q31 was found in MS patients vs. matched non-MS patients. In line, inflammatory disease activity increased in 42% of multiple sclerosis patients after brain tumor radiotherapy suggesting a susceptibility of multiple sclerosis brain tissue to pro-inflammatory stimuli such as ionizing radiation.
Conclusions Concurrent low-grade gliomas should be considered in multiple sclerosis patients with slowly progressive, expansive T2/FLAIR lesions. Our findings of typically reduced extent of resection in MS patients and increased MS activity after radiation inform future treatment decisions.
Key points
– Disease history and sequence of diagnosis differ in MS patients with high-vs low-grade glioma
– Gliomas of MS patients harbor subtle methylation changes in immune-related genetic regions
– Brain tumor radiotherapy is followed by MS disease activity
Importance of the study Immune escape is a hallmark of diffuse glioma, while inflammation is the underlying mechanism of multiple sclerosis. These opposing mechanisms concur in patients that suffer in parallel from multiple sclerosis and glioma. This study is the first to investigate the tumor characteristics, tumor treatment responses and effect on multiple sclerosis activity of a cohort of patients with both diseases. The data warrant caution in the interpretation of suspicious lesions in imaging and suggests risk loci for the observed detrimental effects of radiation specific to MS patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) within CRC1366 Vascular Control of Organ Function, project number 39404578, to KS and MP (project C1) and the Hertie Foundation (P1200013) to KS. MOB acknowledges funding by the Else Kroener-Fresenius Stiftung (2019_EKMS.23).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Tissue sample collection and data collection and use were performed following local ethics regulations and approved by the local ethics committee of Heidelberg University (ethics votes 005/2003, 2013-832R-MA, 2018-614N-MA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) within CRC1366 “Vascular Control of Organ Function”, project number 39404578, to KS and MP (project C1) and the Hertie Foundation (P1200013) to KS. MOB acknowledges funding by the Else Kröner-Fresenius Stiftung (2019_EKMS.23).
Conflict of interest: The authors declare that they have no competing interests.
Authorship: Conception and design: KS, MP. Acquisition of data: all. Analysis of data: KS, TK, DS, FS, MP. Interpretation of data: all. Writing, review, and/or revision of the manuscript: all.
Abbreviations
- CI
- confidence interval
- DMP
- differentially methylated position
- DMR
- differentially methylated region
- HLA
- human leukocyte antigen
- IDH
- isocitrate dehydrogenase
- IL
- interleukin
- MGMT
- O6-methylguanine-DNA methyltransferase
- NAWM
- normal appearing white matter
- OR
- odds ratio
- OS
- overall survival
- PFS
- progression-free survival
- RANO
- response assessment in neuro-oncology
- RT
- radiotherapy
- SVD
- singular value decomposition
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.